


About Genmab

Genmab is an international biotechnology company with a core purpose to improve the lives of patients with cancer. Founded in 1999, Genmab is the creator of multiple approved antibody therapeutics that are marketed by its partners. The company aims to create, develop and commercialize differentiated antibody products by leveraging next-generation antibody technologies, expertise in antibody biology, translational research and data sciences and strategic partnerships. To create novel therapies, Genmab utilizes its next-generation antibody technologies, which are the result of its collaborative company culture and a deep passion for innovation. Genmab's proprietary pipeline consists of modified antibody candidates, including bispecific T-cell engagers and next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.

Our Strengths and Differentiators

- **World-class antibody biology knowledge and deep insight into disease targets**
- **Discovery and development engine with proprietary technologies that allow us to build a world-class pipeline**
- **In-house expertise with solid track record of building successful strategic partnerships**
- **Robust pipeline of potential best-in-class and first-in-class therapies**
- **Experienced, diverse management team**

How we Operate



At-a-glance



Operational


- 4 Approved Medicines Including Genmab's Innovation**
DARZALEX® developed & marketed by Janssen Biotech Inc. Kesimpta® developed & marketed by Novartis. TEPEZZA® developed & marketed by Horizon Therapeutics. RYBREVANT™ developed & marketed by Janssen Biotech Inc.
- 4 Proprietary Technologies**
DuoBody® platform, HexaBody® platform, DuoHexaBody® platform & HexElect® platform
- 8 Proprietary* Antibody Products in Clinical Development**
Tisotumab vedotin, epcoritamab, DuoBody-PD-L1x4-1BB (GEN1046), DuoBody-CD40x4-1BB (GEN1042), HexaBody-DR5/DR5 (GEN1029), DuoHexaBody-CD37 (GEN3009), DuoBody-CD3x5T4 (GEN1044), HexaBody-CD38 (GEN3014)
- 15 Product Candidates Built on Genmab's Innovation**
In clinical development with other companies and royalty streams for Genmab should they come to market. Includes 7 DuoBody products with Janssen

*Tisotumab vedotin 50:50 partnership with Seagen; epcoritamab, DuoHexaBody-CD37 and DuoBody-CD3x5T4 50:50 partnership with AbbVie; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB 50:50 partnership with BioNTech; HexaBody-CD38, exclusive worldwide license and option agreement with Janssen Biotech, Inc.

Financial

DKK 161B 2020 year-end market cap	DKK 16,079M 2020 year-end cash position
DKK 10,111M 2020 revenue 88% increase versus 2019	DKK 3,798M 2020 operating expenses 83% invested in R&D

Operating Result (DKK million)



Our Purpose

To improve the lives of patients with cancer by creating and developing innovative and differentiated antibody products

Our Vision

By 2025, our own product has transformed cancer treatment, and we have a pipeline of knock-your-socks-off antibodies

Our Values

- Passion for innovation
- Determined – being the best at what we do
- Integrity – we do the right thing
- We work as one team & respect each other

Our Strategy

- Focus on core competence
- Turn science into medicine
- Build a profitable and successful biotech

Strong Pipeline of 1st-in-class / Best-in-class Product Candidates



Genmab Proprietary¹ Products

Product	Target	Developed by	Indications	Most Advanced Dev. Phase					Appr.
				Pre-clin.	I	I/II	II	III	
Tisotumab vedotin	TF	Co-developed Genmab/Seagen Inc.	Cervical cancer Ovarian cancer Solid tumors						BLA sub.
Epcoritamab	CD3, CD20	Co-developed Genmab/AbbVie Inc.	R/R DLBCL Hem. malig B-cell NHL (combo) R/R CLL						
DuoBody-PD-L1x4-1BB	PD-L1, 4-1BB	Co-developed Genmab/ BioNTech	Solid tumors						
DuoBody-CD40x4-1BB	CD40, 4-1BB	Co-developed Genmab/ BioNTech	Solid tumors						
HexaBody-DR5/DR5	DR5	Genmab	Solid tumors						
DuoHexaBody-CD37	CD37	Co-developed Genmab/AbbVie Inc.	Hem. malig.						
DuoBody-CD3x5T4	5T4	Co-developed Genmab/AbbVie Inc.	Solid tumors						
HexaBody-CD38	CD38	Genmab ²	Hem. malig.						

Approved Medicines Created by Genmab³

Product	Target	Developed by	Indication(s)	Most Advanced Dev. Phase					
				Pre-clin.	I	I/II	II	III	
Daratumumab	CD38	Janssen	MM ⁴ AL Amyloidosis ⁴ Non-MM blood cancers						
Ofatumumab	CD20	Novartis	RMS ⁴						
Teprotumumab	IGF-1R	Horizon	Thyroid eye disease ⁴ dcSSc						

Programs Incorporating Genmab's Innovation⁵

Amivantamab	DuoBody	Janssen	NSCLC ⁴						
Teclistamab	DuoBody	Janssen	R/R MM						
Talquetamab	DuoBody	Janssen	R/R MM						
Camidanlumab tesirine	UltiMab [®]	ADC Therapeutics	R/R Hodgkin lymphoma Solid tumors						
PRV-015 (AMG 714)	UltiMab	Provention Bio	Celiac disease						
Mim8	DuoBody	Novo Nordisk	Hemophilia A						
JNJ-63709178	DuoBody	Janssen	AML						
JNJ-63898081	DuoBody	Janssen	Solid tumors						
JNJ-67571244	DuoBody	Janssen	R/R AML; MDS						
JNJ-70218902	DuoBody	Janssen	Solid tumors						
HuMax-IL8	UltiMab	BMS	Adv. cancers						
Lu AF82422	UltiMab	Lundbeck	Parkinson's						

Proprietary Technologies Allow us to Build a World-class Pipeline

DuoBody Platform

- Bispecific antibody technology platform
- Potential in cancer, autoimmune, infectious, cardiovascular, central nervous system diseases & hemophilia
- Multiple commercial & research collaborations

HexaBody Platform

- Enhanced potency antibody technology platform
- Broadly applicable technology that builds on natural antibody biology

DuoHexaBody Platform

- Antibody technology that combines
- DuoBody & HexaBody platforms
- Creates bispecific antibodies with target mediated enhanced potency

HexElect Platform

- Antibody technology platform inspired by HexaBody platform
- Combines dual targeting with enhanced selectivity & potency

Executive Management:

Jan G. J. van de Winkel, Ph.D. President & CEO
 Anthony Pagano, EVP & CFO
 Judith Klimovsky M.D., EVP & CDO
 Anthony Mancini, EVP & COO
 Tahamtan Ahmadi, M.D., Ph.D., EVP & CMO, Head of Experimental Medicines

For more information/contact:
genmab.com / ir@genmab.com

¹Certain product candidates in development with partners, as noted ²Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen Biotech, Inc. ³Products developed and marketed by others incorporating Genmab technology and innovation ⁴See local country prescribing information for precise indications ⁵Products under development by a third-party incorporating Genmab's technology and innovation.